Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine for Parkinson's disease hallucinations: clinical efficacy and neurophysiological mechanisms
ChiCTR2200064086Phase 4Not yet recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of quetiapine in Parkinson's disease (PD) (3 arms), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Primary endpoints: Electroencephalogram, Brain MRI and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
quetiapine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2200064086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064086.